OCRF Talk with Lin Zhang, M.D.
OCRF Talk with Lin Zhang, M.D.
In an interview, 3-time grantee Dr. Zhang discusses his research and what it means to receive an award from OCRF.
News
Report from ASCO 2013–What's New in Ovarian Canc...
Report from ASCO 2013–What's New in Ovarian Cancer Research
We recently returned from the annual meeting of the American Society of Clinical Oncology (ASCO), an annual event that gathers thousands of cancer researchers from around the world. Many new studies on or related to ovarian cancer were presented at this year’s ASCO meeting. Click here to read a summary of ovarian cancer research from … Continued
Supreme Court Strikes Down BRCA Gene Patents
Supreme Court Strikes Down BRCA Gene Patents
In a unanimous ruling issued June 13, 2013, the US Supreme Court ruled that private companies do not have the right to patent human genes. In Association for Molecular Pathology et al. v. Myriad Genetics, the court considered the validity of patents held by the Utah-based company Myriad Genetics for the BRCA1 and BRCA2 genes, which … Continued
June 2013 SNMMI Meeting
June 2013 SNMMI Meeting
Society for Nuclear Medicine and Molecular Imaging (SNMMI) Advocate Report from Laurel Pracht As a member of the SNMMI Advocate Advisory Board, formed in 2010 to better bridge the gap between the patient and nuclear medicine communities, I represent the ovarian patient community. Other diseases, including cancer, brain and heart disease are represented as well. … Continued
Press Release: Ovarian Cancer Advocates Praise Supreme Cour...
Press Release: Ovarian Cancer Advocates Praise Supreme Court Decision on Gene Patents
Ruling Will Give Women More Options to Learn About Genetic Risk Washington, DC—The Supreme Court ruled today that a company cannot patent naturally occurring genes, including isolated gene segments, overturning a decision made by the United States Court of Appeals for the Federal Circuit in August 2012, which upheld a patent claim on the BRCA1 … Continued
New Meta-Analysis of Oral Contraception and Risk of Ovarian...
New Meta-Analysis of Oral Contraception and Risk of Ovarian Cancer
A new meta-analysis of more than 6000 studies shows that oral contraceptives significantly reduce the risk of ovarian cancer. The risk reduction increases proportionally with duration of use. See the abstract here
ASCO News: Weekly Chemo Improves Quality of Life
ASCO News: Weekly Chemo Improves Quality of Life
In research presented at the American Society of Clinical Oncology meeting this week, researchers found that shortening the break between chemotherapy sessions improved quality of life for patients, without negatively impacting efficacy. Results from a randomized, phase III trial of over 800 women conducted in Italy showed that lower-dose weekly carboplatin plus paclitaxel was associated … Continued
ASCO News: Kidney Cancer Drug Delays Ovarian Cancer Relapse
ASCO News: Kidney Cancer Drug Delays Ovarian Cancer Relapse
Research presented at the American Society of Clinical Oncology annual meeting this week suggests that adding the drug pazopanib (trade name Votrient) to standard treatment extends progression-free survival in ovarian cancer patients by 5.6 months. Pazopanib is an oral anti-angiogenesis drug already approved to treat kidney cancer. The phase III study of over 900 women … Continued
Partner Member Profile: Nine Girls Ask
Partner Member Profile: Nine Girls Ask
Like many women with ovarian cancer, Joan Wyllie was misdiagnosed by multiple doctors before learning she had stage IV ovarian cancer. Once she learned what was causing her symptoms, Joan recalls, “For some reason, I was not one bit afraid. I knew I would be doing something [to help women with ovarian cancer] but I … Continued
Ovarian Cancer Incidence Fell Along with Hormone Therapy Use
Ovarian Cancer Incidence Fell Along with Hormone Therapy Use
In a study published online in the Journal of Clinical Oncology on May 6, 2013, researchers reported results of a study investigating menopausal hormonal therapy (MHT) use and the incidence of ovarian cancer. When a report from the Women’s Health Initiative linked breast cancer incidence to the use of menopausal hormonal therapy in 2002, there … Continued
Decreases in Ovarian Cancer Correlate to Decrease in Use of...
Decreases in Ovarian Cancer Correlate to Decrease in Use of Hormone Replacement Therapy
A new study shows that rates of ovarian cancer decreased around the same time that the use of hormone replacement therapy dropped off. Overall, for women over 50, rates decreased by 21 percent from 1995 to 2008, from 38 cases out of 100,000 women to 30 out of 100,000. However, the author cautions that this … Continued
Alliance Responds to Angelina Jolie's BRCA1 Announcement
Alliance Responds to Angelina Jolie's BRCA1 Announcement
Actress Angelina Jolie recently announced that she carries a mutation in the BRCA1 gene, which makes her more likely to develop breast and ovarian cancer. In the wake of that news, many media outlets reached out to the Ovarian Cancer National Alliance for commentary and perspective. Our CEO, Calaneet Balas, wrote a letter to the … Continued